Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 8213 results

  1. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Psoriasis: assessment and management (CG153)

    In development Reference number: GID-NG10448 Expected publication date: TBC

    NICE guideline
    In development

  5. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  6. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

    Technology appraisal guidance
    In development

  7. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    In development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    Awaiting development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  15. Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation